Elena Carrara

Elena Carrara

Auto-generated profile, based on publicly available information

Elena Carrara

Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
ETEvelina Tacconelli
Evelina Tacconelli
ECElena Carrara
Elena Carrara
ASAlessia Savoldi
Alessia Savoldi
SHStephan Harbarth
Stephan Harbarth
MMMarc Mendelson
Marc Mendelson
AZAnna Zorzet
Anna Zorzet

1 November 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ASAlessia Savoldi
Alessia Savoldi
ECElena Carrara
Elena Carrara
DGDavid Y. Graham
David Y. Graham
MCMichela Conti
Michela Conti
ETEvelina Tacconelli
Evelina Tacconelli

1 September 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
DBDavid Baur
David Baur
BGBeryl Primrose Gladstone
Beryl Primrose Gladstone
FBFrancesco Burkert
Francesco Burkert
ECElena Carrara
Elena Carrara
FFFederico Foschi
Federico Foschi
ETEvelina Tacconelli
Evelina Tacconelli

13 December 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
ASAnat Stern
Anat Stern
KSKeren Skalsky
Keren Skalsky
TATomer Avni
Tomer Avni
ECElena Carrara
Elena Carrara
LLLeonard Leibovici
Leonard Leibovici
MPMical Paul
Mical Paul

1 December 2020 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
FTFrancesco Taus
Francesco Taus
Gian Luca SalvagnoGian Luca Salvagno
Gian Luca Salvagno
SCStefania Canè
Stefania Canè
Cristiano FavaCristiano Fava
Cristiano Fava
FMFulvia Mazzaferri
Fulvia Mazzaferri
PMPietro Minuz
Pietro Minuz
Objective: Pulmonary thrombosis is observed in severe acute respiratory syndrome coronavirus 2 pneumonia. Aim was to investigate whether subpopulations of platelets were programmed to procoagulant and inflammatory activities in coronavirus disease 2019 (COVID-19) patients with pneumonia, without comorbidities predisposing to thromboembolism. Approach and Results: Overall, 37 patients and 28 healthy subjects were studied. Platelet-leukocyte aggregates, platelet-derived microvesicles, the expression of P-selectin, and active fibrinogen receptor on platelets were quantified by flow cytometry. The profile of 45 cytokines, chemokines, and growth factors released by platelets was defined by immunoassay. The contribution of platelets to coagulation factor activity was selectively measured. Numerous platelet-monocyte (mean±SE, 67.9±4.9%, n=17 versus 19.4±3.0%, n=22; P <0.0001) and platelet-granulocyte conjugates (34.2±4.04% versus 8.6±0.7%; P <0.0001) were detected in patients. Resting patient platelets had similar levels of P-selectin (10.9±2.6%, n=12) to collagen-activated control platelets (8.7±1.5%), which was not further increased by collagen activation on patient platelets (12.4±2.5%, P =nonsignificant). The agonist-stimulated expression of the active fibrinogen receptor was reduced by 60% in patients ( P <0.0001 versus controls). Cytokines (IL [interleukin]-1α, IL-1β, IL-1RA, IL-4, IL-10, IL-13, IL, 17, IL-27, IFN [interferon]-α, and IFN-γ), chemokines (MCP-1/CCL2 [monocyte chemoattractant protein 1]), and growth factors (VEGF [vascular endothelial growth factor]-A/D) were released in significantly larger amounts upon stimulation of COVID-19 platelets. Platelets contributed to increased fibrinogen, VWF (von Willebrand factor), and factor XII in COVID-19 patients. Patients (28.5±0.7 s, n=32), unlike controls (31.6±0.5 s, n=28; P <0.001), showed accelerated factor XII–dependent coagulation. Conclusions: Platelets in COVID-19 pneumonia are primed to spread proinflammatory and procoagulant activities in systemic circulation.

20 January 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
PSParichehr Shamsrizi
Parichehr Shamsrizi
BGBeryl Primrose Gladstone
Beryl Primrose Gladstone
ECElena Carrara
Elena Carrara
DLDora Luise
Dora Luise
ACAndrea Cona
Andrea Cona
ETEvelina Tacconelli
Evelina Tacconelli
Objective: To assess the variation of effect estimates in the analysis of mortality and length of stay (LOS) in patients with infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Design: Systematic review and meta-analysis Methods: Literature search for clinical studies from 1 January 1960 to 1 October 2018 was conducted in PubMed. Primary outcomes were risk ratios (RRs) of all-cause and attributable mortality and weighted mean differences (WMDs) in LOS in patients with bloodstream infections (BSIs) and non-invasive infections. Any change in the effect estimates was assessed by grouping studies according to design, setting, economy-based country classification, reporting period, microbiological aetiology, infection type and adjustment for appropriateness of empirical treatment. The impact of ESBL production was calculated using random-effect meta-analysis and heterogeneity was evaluated by I2 statistics and metaregression. Results: Eighty-four studies including 22 030 patients and 149 outcome measures were included in the meta-analysis. Most studies were retrospective cohorts from high-income countries, providing unadjusted estimates. ESBL production in patients with BSIs (56 studies) increased the RR for all-cause mortality by a factor of 1.70 (95% CI 1.52 to 1.90; p<0.001), attributable mortality (16 studies) by 1.75 (95% CI 1.448 to 2.108; p<0.001) and WMD in the intensive care unit by 3.07 days (95% CI 1.61 to 4.54; p<0.001). WMD in hospital LOS was significantly higher in BSIs (4.41 days; 95% CI 3.37 to 5.46; p<0.001) and non-invasive (2.19 days; 95% CI 1.56 to 2.81; p<0.001). Subgroup analyses showed variation of estimates by study design, population, strain and assessment of appropriateness of empiric treatment. High heterogeneity was observed in all analyses. Conclusions: Current evidence of the clinical burden of infections caused by ESBL-producing bacteria is highly heterogeneous and based mainly on unadjusted estimates derived from retrospective studies. Despite these limitations, ESBL production in strains causing BSIs seems associated with higher all-cause and attributable mortality and longer hospitalisation.